Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
复制标题
在临床抗精神病药物干预效果试验（CATIE）研究中，抗精神病药物对抗精神分裂症患者敌意的有效性。
DOI：
10.1017/s1092852913000849
复制
发表时间：
2014
期刊：
影响因子：
3.3
通讯作者：
VanDorn,RichardA
中科院分区：
文献类型：
--
作者：
Volavka,Jan;Czobor,Pál;Citrome,Leslie;VanDorn,RichardA
简介攻击行为可能是精神分裂症的危险并发症。敌意与攻击性有关。本研究旨在比较奥氮平、奋乃静、利培酮、喹硫平和齐拉西酮对精神分裂症患者敌意的影响。方法我们使用了为期 18 个月的临床抗精神病药物干预效果试验 (CATIE) 研究第一阶段获得的数据。我们分析了 614 名患者的阳性和阴性症状量表 (PANSS) 敌意项目的分数，这些患者在基线时表现出至少最低程度的敌意（分数≥2）。结果敌意的主要分析表明治疗之间存在差异效应（F4,1487 = 7.78，P < 0.0001）。奥氮平在第 1、3、6 和 9 个月时显着优于奋乃静和喹硫平。在第 1、3 和 6 个月时奥氮平也显着优于齐拉西酮，在第 3 和 6 个月时显着优于利培酮。讨论我们的结果与参加欧洲首发精神分裂症的首发精神分裂症受试者的类似事后敌意分析结果一致精神分裂症试验 (EUFEST) 试验中，奥氮平显示出与氟哌啶醇、喹硫平和氨磺必利相比的优势。 结论 与 CATIE 试验第一阶段测试的其他抗精神病药相比，奥氮平在特定的抗敌意作用方面显示出优势。
IntroductionAggressive behavior can be a dangerous complication of schizophrenia. Hostility is related to aggression. This study aimed to compare the effects of olanzapine, perphenazine, risperidone, quetiapine, and ziprasidone on hostility in schizophrenia.MethodsWe used the data that were acquired in the 18-month Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. We analyzed the scores of the Positive and Negative Syndrome Scale (PANSS) hostility item in a subset of 614 patients who showed at least minimal hostility (a score ≥ 2) at baseline.ResultsThe primary analysis of hostility indicated an effect of difference between treatments (F4,1487 = 7.78, P < 0.0001). Olanzapine was significantly superior to perphenazine and quetiapine at months 1, 3, 6, and 9. It was also significantly superior to ziprasidone at months 1, 3, and 6, and to risperidone at months 3 and 6.DiscussionOur results are consistent with those of a similar post-hoc analysis of hostility in first-episode subjects with schizophrenia enrolled in the European First-Episode Schizophrenia Trial (EUFEST) trial, where olanzapine demonstrated advantages compared with haloperidol, quetiapine, and amisulpride.ConclusionOlanzapine demonstrated advantages in terms of a specific antihostility effect over the other antipsychotics tested in Phase 1 of the CATIE trial.